Joel Adams & Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.44M Sell
2,111
-22
-1% -$26K 1.55% 13
2026
Q2
$2.56M Buy
2,133
+1,132
+113% +$1.16M 1.64% 13
2026
Q1
$921K Sell
1,001
-136
-12% -$138K 0.68% 23
2025
Q4
$1.22M Sell
1,137
-31
-3% -$29.6K 0.92% 21
2025
Q3
$891K Sell
1,168
-31
-3% -$23.1K 0.72% 25
2025
Q2
$935K Hold
1,199
– – 0.83% 21
2025
Q1
$990K Hold
1,199
– – 0.89% 20
2024
Q4
$926K Buy
+1,199
New +$993K 0.84% 18

Other funds holding LLY

Joel Adams & Associates's LLY Position: Q3 2026 in Review

Joel Adams & Associates reduced its Eli Lilly (LLY) stake by 1% in Q3 2026, selling an estimated $26K and leaving 2,111 shares worth $2.44M. The position accounts for 1.55% of the portfolio, ranked #13.

Joel Adams & Associates first reported a position in LLY in Q4 2024 and has held it in 8 quarters since. The position peaked at $2.56M in Q2 2026. 4,631 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Joel Adams & Associates held 2,111 shares of Eli Lilly worth $2.44M as of Q3 2026.
  • Joel Adams & Associates sold 22 Eli Lilly shares in Q3 2026, an estimated $26K.
  • Eli Lilly made up 1.55% of Joel Adams & Associates's portfolio in Q3 2026, its #13 holding.
  • Joel Adams & Associates first reported a position in Eli Lilly in Q4 2024 and has held it in 8 quarters since.
  • Joel Adams & Associates's Eli Lilly position peaked at $2.56M in Q2 2026.
  • 4,631 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Joel Adams & Associates's 13F filing for Q3 2026, filed 2 Nov 2026.